dlvr.it
Glucagon-Like Peptide-1 Receptor Agonist and Age-related Macular Degeneration: Adding to the Story
Since the approval of semaglutide for treatment of type 2 diabetes in 2017, use of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RAs) has skyrocketed with 12% of adults reporting having taken the drugs.1 In addition to the treatment of diabetes, the US Food and Drug Administration has approved semaglutide for the treatment of obesity, cardiovascular disease, and metabolic dysfunction–associated steatohepatitis. Furthermore, trials are ongoing for diverse indications, such as drug and alcohol addiction, psoriasis, Parkinson’s disease, and acute pulmonary embolism, supported by a variety of mechanisms of action.